Skip to main content
. Author manuscript; available in PMC: 2021 Mar 15.
Published in final edited form as: Neuropharmacology. 2019 Dec 24;165:107924. doi: 10.1016/j.neuropharm.2019.107924

Figure 2. Corticosterone infusions into the ventral hippocampus differentially alter accumbal dopamine output in (A) saline- and amphetamine pre-treated rats, and (B-C) antagonism of either glucocorticoid- or mineralocorticoid receptors in the ventral hippocampus blocks the effects of corticosterone.

Figure 2.

Data corresponds to mean ± SEM nA. A) Saline- and amphetamine pre-treated rats receiving corticosterone and vehicle infusions into the ventral hippocampus (Table 1). B) saline- or C) amphetamine pre-treated rats receiving ventral hippocampus infusions of mifepristone or spironolactone in combination with corticosterone or vehicle (Table 1), with tracings for vehicle + corticosterone infusions from Fig. 2A shown as dotted lines for comparison. *P < 0.05 vs −2 to −0.5 min (within pre-treatment). #P < 0.05 vs VEH + HBC (within pre-treatment). §P < 0.05 vs pre-treatment. AMP: Amphetamine pre-treatment; CORT: Corticosterone; HBC: hydroxypropyl-β-cyclodextrin; MIF: Mifepristone; SAL: Saline pre-treatment; SPIR: Spironolactone; VEH: Vehicle for antagonists.